nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.12.2012 | Original Paper

Prediction of radiation pneumonitis in lung cancer patients: a systematic review

verfasst von: Xiao-Jing Zhang, Jian-Guo Sun, Jie Sun, Hua Ming, Xin-Xin Wang, Lei Wu, Zheng-Tang Chen

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Factors prediction in the development of radiation pneumonitis (RP) remains unclear. A meta-analysis about this was performed.

Materials

Articles were searched in February 2012 from PubMed, EMBASE, Cochrane Library and CNKI (Chinese Journal Full-text Database) using the keywords “lung cancer,” “radiation pneumonitis” or “radiation lung injury.” The outcome was the RP incidence. We pooled the data using RevMan 5.1 software and tested the statistical heterogeneity.

Results

We included the following factors: age, gender, weight loss, smoking history, complications, performance status, pre-radiation therapy (RT) pulmonary function, TNM, histological type, tumor location, pre-RT surgery, RT combined with chemotherapy (RCT), RT/RCT combined with amifostine, plasma end/pre-RT TGF-β1 ratio and irradiation volume. The significant risk factors for RP ≥ grade 2 were patients with chronic lung disease, tumor located in the middle or lower lobe, without pre-RT surgery, RCT, plasma end/pre-RT TGF-β1 ratio ≥1 and gross tumor volume (GTV). Following factors were identified significant for RP, including tumor located not in the upper lobe, smokers, combined with chronic lung diseases or diabetes mellitus, low pre-RT pulmonary function, RCT, RT/RCT without amifostine and plasma end/pre-RT TGF-β1 ratio ≥1. Dose-volume parameters included the average of mean lung dose (MLD) of disease lung, GTV and V ₅, V ₁₀ (≥34 %), V ₂₀ (≥25 %), V ₃₀ (≥18 %) of bilateral lung.

Conclusions

More attention should be paid to the levels of patients’ pulmonary function, plasma TGF-β1 and dose-volume histogram (DVH). Rigorous studies are needed to identify the relationship between the above-mentioned factors and RP ≥grade 1 or 3.

Abid SH, Malhotra V, Perry MC (2001) Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 13(4):242–248PubMedCrossRef

An JY, Kwon SJ, Lee YS et al (2004) Factors predicting the development of radiation pneumonitis in the patients receiving radiation therapy for lung cancer. Tuberc Respir Dis 56(1):40–50

Anscher MS, Kong FM, Andrews K et al (1998) Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 41(5):1029–1035PubMedCrossRef

Antonadou D (2002) Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer. Semin Radiat Oncol 12(1 Suppl 1):50–58PubMedCrossRef

Antonadou D, Coliarakis N, Synodinou M et al (2001) Randomized phase III trial of radiation treatment ± amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 51(4):915–922PubMedCrossRef

Antonadou D, Petridis A, Synodinou M et al (2003) Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Semin Oncol 30(6 Suppl 18):2–9PubMedCrossRef

Barriger RB, Fakiris AJ, Hanna N, Yu M, Mantravadi P, Mcgarry RC (2010) Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. Int J Radiat Oncol Biol Phys 78(5):1381–1386PubMedCrossRef

Barriger RB, Forquer JA, Brabham JG et al (2012) A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 1(82):457–462CrossRef

Cai Y, Zhou D (2011) Analysis of risk factors of radiation pneumonitis in non-small cell lung cancer. Chin J Nosocomiol 21(16):3357–3359 (article in Chinese)

Chang DT, Olivier KR, Morris CG et al (2006) The impact of heterogeneity correction on dosimetric parameters that predict for radiation pneumonitis. Int J Radiat Oncol Biol Phys 65(1):125–131PubMedCrossRef

Choi NC (2003) Radioprotective effect of amifostine in radiation pneumonitis. Semin Oncol 30:10–17PubMedCrossRef

Claude L, Pérol D, Ginestet C et al (2004) A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol 71(2):175–181PubMedCrossRef

Clenton SJ, Fisher PM, Conway J, Kirkbride P, Hatton MQ (2005) The use of lung dose-volume histograms in predicting post-radiation pneumonitis after non-conventionally fractionated radiotherapy for thoracic carcinoma. Clin Oncol (R Coll Radiol) 17(8):599–603CrossRef

Dang J, Li G, Lu X et al (2010) Analysis of related factors associated with radiation pneumonitis in patients with locally advanced non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. J Cancer Res Clin Oncol 136(8):1169–1178PubMedCrossRef

Das SK, Chen S, Deasy JO, Zhou S, Yin FF, Marks LB (2008) Combining multiple models to generate consensus: application to radiation-induced pneumonitis prediction. Med Phys 35(11):5098–5109PubMedCrossRef

De Petris L, Lax I, Sirzén F, Friesland S (2005) Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer. Med Oncol 22(4):375–381PubMedCrossRef

De Ruysscher D, Wanders R, van Haren E et al (2008) HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 71(1):132–138PubMedCrossRef

Evans ES, Kocak Z, Zhou SM et al (2006) Does transforming growth factor-beta1 predict for radiation-induced pneumonitis in patients treated for lung cancer? Cytokine 5(3–4):186–192CrossRef

Fay M, Tan A, Fisher R, Mac Manus M, Wirth A, Ball D (2005) Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 61(5):1355–1363PubMedCrossRef

Fu XL, Huang H, Bentel G et al (2001) Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys 50(4):899–908PubMedCrossRef

Fujino M, Shirato H, Onishi H et al (2006) Characteristics of patients who developed radiation pneumonitis requiring steroid therapy after stereotactic irradiation for lung tumors. Cancer J 12(1):41–46PubMedCrossRef

Hildebrandt MA, Komaki R, Liao Z et al (2010) Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One 5(8):e12402PubMedCrossRef

Hope AJ, Lindsay PE, EI Naqa I et al (2006) Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys 65(1):112–124PubMedCrossRef

Huang EX, Hope AJ, Lindsay PE et al (2011) Heart irradiation as a risk factor for radiation pneumonitis. Acta Oncol 50(1):51–60PubMedCrossRef

Inoue A, Kunitoh H, Sekine I, Sumi M, Tokuuye K, Saijo N (2001) Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 49(3):649–655PubMedCrossRef

Ishii Y, Kitamura S (1999) Soluble intercellular adhesion molecule-1 as an early detection marker for radiation pneumonitis. Eur Respir J 13(4):733–738PubMedCrossRef

Kim TH, Cho KH, Pyo HR et al (2005) Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology 235(1):208–215PubMedCrossRef

Kim JY, Kim YS, Kim YK et al (2009) The TGF-beta1 dynamics during radiation therapy and its correlation to symptomatic radiation pneumonitis in lung cancer patients. Radiat Oncol 4:59PubMedCrossRef

Kobayashi H, Uno T, Isobe K et al (2010) Radiation pneumonitis following twice-daily radiotherapy with concurrent carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer. Jpn J Clin Oncol 40(5):464–469PubMedCrossRef

Kocak Z, Yu X, Zhou SM et al (2005) The impact of pre-radiotherapy surgery on radiation-induced lung injury. Clin Oncol (R Coll Radiol) 17(4):210–216CrossRef

Komaki R, Lee JS, Kaplan B et al (2002) Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol 12(1 Suppl 1):46–49PubMed

Komaki R, Lee JS, Milas L et al (2004) Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58(5):1369–1377PubMedCrossRef

Kong FM, Anscher MS, Sporn TA et al (2001) Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury. Int J Radiat Oncol Biol Phys 49(1):35–41PubMedCrossRef

Kong FM, Hayman JA, Griffith KA et al (2006) Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 65(4):1075–1086PubMedCrossRef

Koto M, Tsujii H, Yamamoto N, Nishimura H, Yamada S, Miyamoto T (2007) Dosimetric factors used for thoracic X-ray radiotherapy are not predictive of the occurrence of radiation pneumonitis after carbon-ion radiotherapy. Tohoku J Exp Med 213(2):149–156PubMedCrossRef

Lee SW, Choi EK, Lee JS et al (2003) Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 56(4):996–1004PubMedCrossRef

Li Y, Zhu SC, Chi ZF (2007) Analysis on the risk factors of radiation pneumonitis after three-dimensional radiotherapy in lung cancer patients. Cancer Res Prev Treat 34(8):586–589 (article in Chinese)

Mak RH, Alexander BM, Asomaning K, et al (2011) A single-nucleotide polymorphism in the MTHFR (methylene tetrahydrofolate reductase) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy. Cancer. [Epub ahead of print]

Makimoto T, Tsuchiya S, Hayakawa K, Saitoh R, Mori M (1999) Risk factors for severe radiation pneumonitis in lung cancer. Jpn J Clin Oncol 29(4):192–197PubMedCrossRef

Mao J, Kocak Z, Zhou S et al (2007) The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response. Int J Radiat Oncol Biol Phys 67(5):1360–1369PubMedCrossRef

Matsuno Y, Satoh H, Ishikawa H, Kodama T, Ohtsuka M, Sekizawa K (2006) Simultaneous measurements of KL-6 and SP-D in patients undergoing thoracic radiotherapy. Med Oncol 23(1):75–82PubMedCrossRef

Mehta V (2004) Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer. Semin Oncol 31:42–46PubMedCrossRef

Monson JM, Stark P, Reilly JJ et al (1998) Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer 82(5):842–850PubMedCrossRef

Nakayama Y, Makino S, Fukuda Y, Min KY, Shimizu A, Ohsawa N (1996) Activation of lavage lymphocytes in lung injuries caused by radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 34(2):459–467PubMedCrossRef

Novakova-Jiresova A, Van Gameren MM, Coppes RP, Kampinga HH, Groen HJ (2004) Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol 71(2):183–189PubMedCrossRef

Oh D, Ahn YC, Park HC, do Lim H, Han Y (2009) Prediction of radiation pneumonitis following high-dose thoracic radiation therapy by 3 Gy/fraction for non-small cell lung cancer: analysis of clinical and dosimetric factors. Jpn J Clin Oncol 39(3):151–157PubMedCrossRef

Parashar B, Edwards A, Mehta R et al (2011) Chemotherapy significantly increases the risk of radiation pneumonitis in radiation therapy of advanced lung cancer. Am J Clin Oncol 34(2):160–164PubMed

Piotrowski T, Matecka-Nowak M, Milecki P (2005) Prediction of radiation pneumonitis: dose-volume histogram analysis in 62 patients with non-small cell lung cancer after three-dimensional conformal radiotherapy. Neoplasma 52(1):56–62PubMed

Ramella S, Trodella L, Mineo TC et al (2010) Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy. Int J Radiat Oncol Biol Phys 76(1):110–115PubMedCrossRef

Rancati T, Ceresoli GL, Gagliardi G et al (2003) Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 67(3):275–283PubMedCrossRef

Robnett TJ, Machtay M, Vines EF et al (2000) Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 48(1):89–94PubMedCrossRef

Roeder F, Friedrich J, Timke C et al (2010) Correlation of patient-related factors and dose-volume histogram parameters with the onset of radiation pneumonitis in patients with small cell lung cancer. Strahlenther Onkol 186(3):149–156PubMedCrossRef

Saynak M, Higginson DS, Morris DE, Marks LB (2010) Current status of postoperative radiation for non-small-cell lung cancer. Semin Radiat Oncol 20:192–200PubMedCrossRef

Schild SE, Stella PJ, Geyer SM et al (2003) The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21(17):3201–3206PubMedCrossRef

Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother 1(2):100–107PubMedCrossRef

Segawa Y, Takigawa N, Kataoka M, Takata I, Fujimoto N, Ueoka H (1997) Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer. Int J Radiat Oncol Biol Phys 39(1):91–98PubMedCrossRef

Shi A, Zhu G, Wu H, Yu R, Li F, Xu B (2010) Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy. Radiat Oncol 5:35PubMedCrossRef

Song H, Yu JM (2009) Effect of diabetes mellitus on the development of radiation pneumonitis in patients with non-small cell lung cancer. Chin J Oncol 1:45–47 (article in Chinese)

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605PubMedCrossRef

Takahashi H, Imai Y, Fujishima T et al (2001) Diagnostic significance of surfactant proteins A and D in sera from patients with radiation pneumonitis. Eur Respir J 17(3):481–487PubMedCrossRef

Tsujino K, Hirota S, Endo M et al (2003) Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 55(1):110–115PubMedCrossRef

Tucker SL, Jin H, Wei X et al (2010) Impact of toxicity grade and scoring system on the relationship between mean lung dose and risk of radiation pneumonitis in a large cohort of patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 77(3):691–698PubMedCrossRef

Uno T, Isobe K, Kawakami H et al (2006) Dose-volume factors predicting radiation pneumonitis in patients receiving salvage radiotherapy for postlobectomy locoregional recurrent non-small-cell lung cancer. Int J Clin Oncol 11(1):55–59PubMedCrossRef

Vinogradskiy Y, Tucker SL, Liao Z, Martel MK (2012) Investigation of the relationship between gross tumor volume location and pneumonitis rates using a large clinical database of non-small-cell lung cancer patients. Int J Radiat Oncol Biol Phys 82(5):1650–1658

Vogelius IS, Bentzen S (2010) Clinical factors associated with risk of radiation pneumonitis: a literature based meta-analysis. Radiother Oncol 96:S125–S126

Vujaskovic Z, Groen HJ (2000) TGF-beta, radiation-induced pulmonary injury and lung cancer. Int J Radiat Biol 76(4):511–516PubMedCrossRef

Wang LW, Fu XL, Clough R et al (2000) Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis. Radiat Res 153(4):405–410PubMedCrossRef

Wang Y, Wang L, Feng Q et al (2005) Factors predicting radiation toxicity in the treatment of three-dimensional conformal radiotherapy for lung cancer. Chin J Lung Cancer 8(5):454–458 (article in Chinese)PubMed

Wang WH, Bao Y, Chen M et al (2006) Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer. Chin J Cancer 25(10):1279–1283 (article in Chinese)PubMed

Wang J, Qiao XY, Cao YK et al (2009) Analysis of correlated factors of radiation pneumonitis after three-dimensional conformal radiotherapy for non-small cell lung cancer. Chin J Clin Oncol 36(19):1086–1089 (article in Chinese)

Wang J, Qiao XY, Lu FH et al (2010) TGF-beta1 in serum and induced sputum for predicting radiation pneumonitis in patients with non-small cell lung cancer after radiotherapy. Chin J Cancer 29(3):325–329 (article in Chinese)PubMedCrossRef

Watanabe H, Suga A, Tsuchihashi Y et al (1995) Clinical study of radiation pneumonitis over 10 years. Nihon Kyobu Shikkan Gakkai Zasshi 33(4):384–388PubMed

Xiao C, Ding HJ, Feng LC, Qu BL, Dou YQ (2010) Efficacy of Liangxue Jiedu Huoxue Decoction in prevention of radiation pneumonitis: a randomized controlled trial. J Chin Integr Med 8(7):624–628 (article in Chinese)PubMedCrossRef

Xie SX, Li WX, Lin YR, Zou WC (2006) Three-dimensional conformal hypofractionated radiotherapy for non-small-cell lung cancer. Chin oncol 16(12):1034–1037 (article in Chinese)

Yamada M, Kudoh S, Hirata K, Nakajima T, Yoshikawa J (1998) Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer 34(1):71–75PubMedCrossRef

Yamano M, Ogino H, Shibamoto Y, Horii N (2007) Relationship between radiation pneumonitis and prognosis in patients with primary lung cancer treated by radiotherapy. Kurume Med J 54(3–4):57–63PubMedCrossRef

Yin M, Liao Z, Huang YJ et al (2011) Polymorphisms of homologous recombination genes and clinical outcomes of non-small cell lung cancer patients treated with definitive radiotherapy. PLoS One 6(5):e20055PubMedCrossRef

Yorke ED, Jackson A, Rosenzweig KE, Braban L, Leibel SA, Ling CC (2005) Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 63(3):672–682PubMedCrossRef

Yu X, Yang Z, Wang G et al (2011) Correlative factor analysis of radiation pneumonitis in 62 locally advanced NSCLC cases treated with 3DCRT. Mod Oncol 19(6):1120–1122 (article in Chinese)

Zhang B, Qiao TK (2010) Predictors of pulmonary lesion induced by three dimensional conformal radiotherapy combined with chemotherapy of np for iii stage non-small cell lung cancer. Cancer Res Prev Treat 37(5):578–581 (article in Chinese)

Zhang L, Yang M, Bi N et al (2010) ATM polymorphisms are associated with risk of radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 77(5):1360–1368PubMedCrossRef

Zhao L, Wang L, Ji W et al (2007) Association between plasma angiotensin-converting enzyme level and radiation pneumonitis. Cytokine 37(1):71–75PubMedCrossRef

Zhong J, Liu J, Chen WX (2007) Relationship between the plasma transforming growth factor-β1 levels and radiation-induced lung injury. Pract J cancer 22(5):468–471 (article in Chinese)

Titel: Prediction of radiation pneumonitis in lung cancer patients: a systematic review
verfasst von: Xiao-Jing Zhang
Jian-Guo Sun
Jie Sun
Hua Ming
Xin-Xin Wang
Lei Wu
Zheng-Tang Chen
Publikationsdatum: 01.12.2012
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2012
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-012-1284-1

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Prediction of radiation pneumonitis in lung cancer patients: a systematic review

Abstract

Purpose

Materials

Results

Conclusions

Neu im Fachgebiet Onkologie

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Materials

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2012

Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth

Effects of CDC7 gene silencing and Rituximab on apoptosis in diffuse large B cell lymphoma cells

Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer

Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis

First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly ‘unfrail’ patients with advanced non-small-cell lung cancer: a multicenter phase II study

A combined approach identifies three mRNAs that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7

Neu im Fachgebiet Onkologie

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Update Onkologie